Pittenger & Anderson Inc. Cuts Position in Zoetis Inc. (NYSE:ZTS)

Pittenger & Anderson Inc. decreased its holdings in Zoetis Inc. (NYSE:ZTS) by 4.9% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 119,377 shares of the company’s stock after selling 6,187 shares during the period. Pittenger & Anderson Inc.’s holdings in Zoetis were worth $19,450,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of ZTS. AMF Tjanstepension AB raised its holdings in Zoetis by 23.4% in the third quarter. AMF Tjanstepension AB now owns 105,376 shares of the company’s stock valued at $20,594,000 after buying an additional 20,001 shares during the period. Exchange Traded Concepts LLC raised its stake in shares of Zoetis by 4,582.9% during the third quarter. Exchange Traded Concepts LLC now owns 1,639 shares of the company’s stock valued at $320,000 after purchasing an additional 1,604 shares during the period. Creative Planning raised its stake in shares of Zoetis by 8.6% during the third quarter. Creative Planning now owns 90,401 shares of the company’s stock valued at $17,663,000 after purchasing an additional 7,170 shares during the period. Trust Co. of Vermont raised its stake in shares of Zoetis by 24.8% during the third quarter. Trust Co. of Vermont now owns 1,123 shares of the company’s stock valued at $219,000 after purchasing an additional 223 shares during the period. Finally, Howard Capital Management Group LLC raised its stake in shares of Zoetis by 0.8% during the third quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company’s stock valued at $20,489,000 after purchasing an additional 883 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Insider Activity

In other news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Zoetis Stock Performance

Zoetis stock opened at $157.54 on Monday. The company has a market cap of $71.08 billion, a PE ratio of 29.61, a P/E/G ratio of 2.77 and a beta of 0.90. The company has a fifty day moving average price of $168.51 and a two-hundred day moving average price of $178.78. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.53.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Research analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.27%. The ex-dividend date is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is 37.59%.

Wall Street Analyst Weigh In

ZTS has been the topic of a number of analyst reports. UBS Group initiated coverage on shares of Zoetis in a research note on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective on the stock. Stifel Nicolaus dropped their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Piper Sandler decreased their price target on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Morgan Stanley decreased their price target on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research report on Friday. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $214.90.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.